U.S. markets closed

Hoth Therapeutics, Inc. (HOTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4150-0.0042 (-1.00%)
At close: 04:00PM EDT
0.4140 -0.00 (-0.24%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close0.4192
Bid0.4050 x 1200
Ask0.4200 x 3100
Day's Range0.4000 - 0.4291
52 Week Range0.3800 - 1.7500
Avg. Volume4,109,470
Market Cap13.367M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-0.5280
Earnings DateNov 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for HOTH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Hoth Therapeutics, Inc.
    Technical Assessment: Bearish in the Intermediate-TermMonday provided a much-needed rest for the stock market after a very large rebound last week. Following that strong week (and we've seen this before during the current decline), the "bottom-callers" are out, but not in big numbers. That's probably a good thing, as others are calling this another bear-market rally. From a technical perspective and using our own interpretation, it is far too early to call the bottom as there is just not enough of the needed evidence.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • PR Newswire

    Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

    Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("Hoth" or the "Company") today announced that the Company received confirmation from the Listing Qualification Department of The NASDAQ Capital Market ("Nasdaq") notifying the Company that Nasdaq has granted the Company an additional 180-day compliance period, or until December 26, 2022, to regain compliance with Nasdaq's minimum $1.00 closing bid price per share requirement (the "Additional Compliance Period").

  • PR Newswire

    Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate the next phase of its BioLexa trial for patients suffering with Atopic Dermatitis.

  • PR Newswire

    Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that its Annual Meeting of Shareholders scheduled for and convened on June 15, 2022 (the "Annual Meeting") was adjourned until 12:00 p.m. Eastern Time on June 23, 2022 to allow additional time to solicit proxies and obtain a quorum for the Annual Meeting. No business other than the adjournment was conducted on June 15, 2022. The Annual Meeting to be held on June 23, 2022 will be held virtually at